First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Mark YarchoanJohn D PowderlyBruno R BastosThomas Benjamin KarasicOxana V CryslerPamela N MunsterMeredith A McKeanLeisha A EmensYvonne M SaengerYasser GedRobert StaggSteven SmithChan C WhitingAnne MoonPeppi PrasitYonchu JenkinsNathan StandiferThomas W DubenskySam H WhitingSusanna V UlahannanPublished in: Cancer research communications (2024)
TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.